Preview

Опухоли женской репродуктивной системы

Расширенный поиск

КЛИНИКО-МОРФОЛОГИЧЕСКИЕ И МОЛЕКУЛЯРНО-БИОЛОГИЧЕСКИЕ ФАКТОРЫ ПРОГНОЗА РЕДКИХ ФОРМ РАКА ТЕЛА МАТКИ

https://doi.org/10.17650/1994-4098-2008-0-2-60-69

Полный текст:

Аннотация

КЛИНИКО-МОРФОЛОГИЧЕСКИЕ И МОЛЕКУЛЯРНО-БИОЛОГИЧЕСКИЕ ФАКТОРЫ ПРОГНОЗА РЕДКИХ ФОРМ РАКА ТЕЛА МАТКИ

Об авторах

К. П. Лактионов
НИИ клинической онкологии ГУ РОНЦ им. Н.Н. Блохина РАМН, Москва
Россия


Г. М. Абдуллаева
НИИ клинической онкологии ГУ РОНЦ им. Н.Н. Блохина РАМН, Москва
Россия


О. А. Анурова
НИИ клинической онкологии ГУ РОНЦ им. Н.Н. Блохина РАМН, Москва
Россия


Список литературы

1. Lauchlan S.C. Tubal (serous) carcino- ma of the endometrium. Arch Pathol Lab Med 1981;105:615—8.

2. Hendrickson M., Ross J., Eifel P.J. Adenocarcinoma of the endometium: analysis of 256 cases with carcinoma lim- ited to the uterine corpus. Gynecol Oncol 1982;13:373—92.

3. Trope C., Kristensen G.B., Abeler V.M. Clear-cell and papillary serous cancer: treatment options. Baillieres. Best Pract Res Clin Obstet Gynecol 2001;15(3):433—46.

4. Hamilton C.A., Cheung M.K., Osann K. et al. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Brit J Cancer 2006;94:642—6.

5. Ульрих Е.А., Нейштадт Э.Л. Редкие формы рака тела матки. Практ онкол 2004;5(1):68—76.

6. Novak E. Gynecological and Obstetrical Pathology. Philadelphia, Sanders W.B.; 1947. p. 225—4.

7. Craighead P.S., Sait K., Gavin C.S. et al. Management of aggressive histolog- ic variants of endometrial carcinoma at the Tom Baker Cancer Centre between 1984 and 1994. Gynecol Oncol 2000;77:248—53.

8. Matthews R.P., Hutchinson-Colas J., Maiman M. et al. Papillary serous and clear cell type lead to poor prognosis of endometrial carcinoma in black women. Gynecol Oncol 1997;65:206—12.

9. Ульрих Е.А., Нейштадт Э.Л., Зельдович Д.Р., Урманчеева А.Ф. Комплексное лечение больных серозно-папиллярным раком. Материалы науч.-практ. конф., посвящ. 85-летию со дня основания ЦНИРРИ МЗ РФ. СПб.; 2003. с. 233—4.

10. Урманчеева А.Ф., Ульрих Е. А., Нейштадт Э.Л. и др. Серозно- папиллярный рак эндометрия (клинико-морфологические особенности. Вопр онкол 2002;48(6):679—83.

11. Halperin R., Zebavi S., Habler L. et al. Comparative immunohistochemical study of endometrioid and serous papil- lary carcinoma of endometrium. Eur J Gynecol Oncol 2001;22(2):122—6.

12. Slomovitz B.M., Burke T.W., Eifel P.J. et al. Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases. Gynecol Oncol 2003;91(3):463—9.

13. Hendrickson M., Ross J., Eifel P. et al. Uterine papillary carcinoma: a highly malignant from of endometrial adenocarcinoma. Am J Surg Pathol 1982;6(2):93—108.

14. Gallion H.H., Van Nagell J.R., Koborn E.I. et al. Stage I papillary carci- noma of endometrium. Cancer 1989;63:2224—8.

15. Scully R.E., Barlow J.F. Mesonephroma of ovary. Tumor of Mullerian nature related to the endometrioid carcinoma. Cancer 1967;20:1405—17.

16. Silverberg S., Kurman R. Tumours of the uterine corpus and gestational tro- phoblastic disease. Washington. Armed Forces Institute of Pathology; 1992. p. 240—88.

17. Abeler V.M., Vergote I.B., Kjorstad K.E. et al. Clear-cell carcinoma of the endometrium. Prognostic and metastatic pattern. Cancer 1996;78:1740—7.

18. Murphy K.T., Rotmensch J., Yamada S.D. et al. Outcome and patterns of failure in patologic stages I-IV clear- cell carcinoma of the endometrium: implications for adjuvant radiation thera- py. Int J Radiat Oncol Biol Phys 2003; 55(5):1272—6.

19. Clement P.B, Young R.H. Non-endometrioid carcinomas of the uterine corpus: a review of their patholo- gy with emphasis on recent advances and problematic aspects. Adv Anat Pathol 2004;11:117—42.

20. Ross J.C., Eifel P.J., Cox R.S. et al. Primary mucinous adenocarcinoma of the endometrium. A clinicopathologic and histochemical study. Am J Surg Pathol 1983;7:715—29.

21. Dallenbach-Hellweg G., Hahn U. Mucinous and clear cell adenocarcino- mas of the endometrium in patients receiving antiestrogens (tamoxifen) and gestagens. Int J Gynecol Patol 1995;14:7—15.

22. Rodolakis A., Papaspyrou I., Sotiropoulou M. et al. Primary squamous cell carcinoma of the endometrium. A report of 3 cases. Eur J Gynaecol Oncol 2001;22:143—6.

23. Shidara Y. Karube A., Watanabe M. et al. A case report: verrucous carcinoma of the endometrium - the difficalty of diagnosis and a review of the literature. J Obstet Gynaecol Res 2000;26:189—92.

24. Kataoka A., Nishida T., Sugiyama T. et al. Squamous cell carcinoma of the endometrium with human papillomavirus type 31 and without tumor suppressor gene p53 mutation. Gynecol Oncol 1997;65:180—4.

25. Sherman M.E., Bitterman P., Rosenbein N.B. et al. Uterine papillary carcinoma. A morphologically disease neoplasm with unifying clinicopathologic features. Am J Surg Pathol 1992;16(6):600—10.

26. Carcangiu M.L., Cambers J.T. Uterine papillary serous carcinoma. A study on 108 cases with emphasis on the prognostic significance of associated endometrioid carcinoma, absence of invasion, and concomitant ovarian carci- noma. Gynecol Oncol 1992;47:298—305.

27. Goff B.A., Kato D., Schmidt R.A. et al. Uterine papillary serous carcinoma: Patterns of metastatic spread. Gynecol Oncol 1994;554:264—8.

28. Williams K.E., Waters E.D., Woolas R.P. et al. Mixed serous- endometrioid carcinoma of the uterus. Paphologic and cytopaphologic analysis of high-risk endometrial carcinoma. Int J Gynecol Cancer 1994;4:7—18.

29. Lim P., Al Kushi A, Gilks B. et al. Early stage uterine papillary serous carci- noma of the endometrium. Cancer 2001;91:752—7.

30. Wheeler D.T., Bell K.A., Kurman R.J. et al. Minimal uterine serous carcinoma. Am J Surg Pathol 2000;24:797—806.

31. Бохман Я.В. Руководство по онкогинекологии. Л., Медицина; 1989. с. 275—340.

32. Cirisano F.D., Robboy S.J., Dodge R.K. et al. The outcome of stage I-II clinically and surgically staged papil- lary serous and clear cell endometrial cancers when compared with endometri- oid carcinoma. Gynecol Oncol 2000;77:55—65.

33. Харитонова Т.В. Рак тела матки. Совр онкол 2000;2(2):4—10.

34. Erdem O., Erdem M., Dursun A. et al. Angiogenesis, p53, and bcl-2 expression as prognostic indicators in endometrial cancer: comparison with tra- ditional clinicopatologic variables. Int J Gynecol Patol 2003;22:254—60.

35. Susini T., Amunni G., Molino C. et al. Ten-years results of prospective study on the prognostic role of ploidy in endometrial carcinoma. Cancer 2007;109(5):882—90.

36. Chan J.K., Lozzi V., Youssef M. et al. Significance of comprehensive sur- gical staging in noninvasive papillary serous carcinoma of the endometrium. Gynecol Oncol 2003;90:181—5.

37. Huh W.K., Powell M., Leath III C.A. et al. Uterine papillary serous carcinoma: comparisons of out- comes in surgical stage I patients with and without adjuvant therapy. Gynecol Oncol 2003;91:470—5.

38. Creasman W.T., Kohler M.F., Odicino F. et al. Prognosis of papillary serous, clear cell, and grade 3 stage I car- cinoma of the endometrium. Gynecol Oncol 2004;95:593—6.

39. Boruta D.M. 2nd, Gehrig P.A., Groben P.A. et al. Uterine serous and grade 3 endometrioid carcinomas: is there a survival difference? Cancer 2004;101:2214—21.

40. Khalifa M.A., Mannel R.S., Haraway S.D. et al. Expression of EGFR, Her-2/neu, P53 and PCNA in endometrioid, serous papillary and clear cell endometrial adenocarcinomas. Gynecol Oncol 1994;53:84—92.

41. Athanassiadou P., Athanassiades P., Grapsa D. et al. The prognostic value of PTEN, p53 and β-catenin in endometrial carcinoma: a prospective immunocyto- chemical study. Int J Gynecol Cancer

42. ;17(3):697—704.

43. Alektiar V.M., McKee A., Lin O. et al. Is there a difference in outcome between stage I—II endometrial cancer of papillary serous/clear cell and endometri- oid FIGO Grade 3 cancer? Int J Radiat Oncol Biol Phys 2002;54:79—85.

44. Pradhan M., Abeler V.M., Danielsen H.E. et al. Image cytometry DNA ploidy correlates with histological subtypes in endometrial carcinomas. Mod Pathol 2006;19(9):1227—35.

45. Alkuchi A., Lim P., Coldman A. et al. Interpretation of p53 immunoreac- tivity in endometrial carcinoma: estab- lishing a clinically relevant cut-off level. Int J Gynecol Pathol 2004;23(2): 129—37.

46. Osmanagaoglu M.A., Kadioglu S., Osmanagaoglu S. et al. The relationship between mutant p53gene, DNA contents and conventional clinicopatological prog- nostic variables in cases with endometrial carcinoma. Eur J Gynecol Oncol 2005;26(1):64—70.

47. Geisler J.P., Geisler H.E., Wiemann M.C. et al. P53 expression as a prognostic indicator of 5-year survival in endometrial cancer. Gynecol Oncol 1999;74(3):468—71.

48. Oreskovic S., Babic D., Kalafatic D. et al. A significance of immunohisto- chemical determination of steroid recep- tors, cell proliferation factor Ki-67 and protein p53 in endometrial carcinoma. Gynecol Oncol 2004;93(1):34—40.

49. Kounelis S., Kapranos N., Kouri E. et al. Immunohistochemical profile of endometrial adenocarcinoma: a study of 61 cases and review of the literature. Mod Pathol 2000;13(4):379—88.

50. Inaba F., Kawamata H., Teramoto T. et al. PTEN and p53 abnormalities are indicative and predicative factors for endometrial carcinoma. Oncol Rep 2005;13(1):17—24.

51. Wu H., Goel V., Haluska F.G. PTEN signaling pathways in melanoma. Oncogene 2003;22(20):3113—22.

52. Wijnhoven B.P., Dinjens W.N., Pignatelli M. E-cadherin-catenin cell- cell adhesion complex and human can- cer. Brit J Surg 2000;87(8):992—1005.

53. Stefansson I.M., Salvensen H.B., Akslen L.A. Prognostic impact of alter- ations in P-cadherin expression and related cell adhesion markers in endome- trial cancer. J Clin Oncol 2004;22: 1242—52.

54. Bremnes R.M., Veve R., Hirsch F.R. et al. The E-cadherin cell-cell adhesion complex and cancer invasion, metastasis, and prognosis. Lung Cancer 2002;36(2):115—24.

55. Kim Y.T., Choi E.K., Kim J.W. et al. Expression of E-cadherin and α-, β-, γ- catenin proteins in endometrial carcino- ma. Yonsei Med J 2002;43:701—11.

56. Matsui S., Shiozaki H., Inoue M. et al. Immunohistochemical evaluation of alpha-catenin expression in human gas- tric cancer. Virchows Arch 1994;424(4):375—81.

57. Jawhari A., Jordan S., Poole S. et al. Abnormal immunoreactivity of the E- cadherin-catenin complex in gastric car- cinoma: relationship with patient sur- vival. Gastroenterology 1997;112(1): 46—54.

58. Mell L.K., Meyer J.J., Tretiakova M. et al. Prognostic significance of E- cad- herin protein expression in pathological stage I—III endometrial cancer. Clin Cancer Res 2004;10:5546—53.

59. Sakuragi N., Nishiya M., Ikeda K. et al. Decreased E-cadherin expression in endometrial carcinoma is associated with tumor dedifferentiation and deep myometrial invasion. Gynecol Oncol 1994;53:183—9.

60. Schlosshauer P.W., Ellenson L.N., Soslow R.A. Beta-catenin and E-cad- herin expression patterns in high-grade endometrial carcinoma are associated with histological subtype. Mod Pathol 2002;15(10):1032—7.

61. Tecimer C., Doering D.L., Coldsmith L.J. et al. Clinical relevance of urokinase-type plasmogen activator, its receptor, and its inhibitor type 1 in endometrial cancer. Gynecol Oncol 2001;80(1):48—55.

62. Memarzadeh S., Kozak K.R., Chang L. et al. Urokinase plasminogen activator receptor. Prognostic biomarker for endometrial cancer. Proc Natl Acad Sci USA 2002;99(16):10647—52.

63. Karahan N., Guney M., Baspinar S. et al. Expression of gelatinase (MMP-2 and MMP-9) and cyclooxyge- nase-2 (COX-2) in endometrial carcino- ma. Eur J Gynecol Oncol 2007;28(3):184—8.

64. Lynch C.C., Matrisian L.M. Matrix metalloproteinases in tumor-host cell communication. Differentiation 2002;70(9-10):561—73.

65. Klapper L.N., Waterman H., Sela M. Tumor-inhibitory antibodies to Her-2/ErbB2 may act by recruiting c-Clb and enhancing ubiquitination of Her-2. Cancer Res 2000;60(13):3384—8.

66. Yu D., Hung M.C. Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. Oncogene 2000;19:6115—21.

67. Coronado P.J., Vidart J.A., Lopez-asenjo J.A. et al. P53 overexpres- sion predicts endometrial carcinoma recurrence better than HER-2/neu over- expression. Eur J Obstet Gynecol Reprod Biol 2001;98(1):103—8.

68. Santin A.D., Bellone S., Gokden M. et al. Overexpression of Her-2/neu in uterine serous papillary cancer. Clin Cancer Res 2002;8:1271—9.

69. Geisinger K.R., Homesley H.D., Morgan T.M. Endometrial adenocarcino- ma: a multiparameter clinicopathologic analysis including the DNA profile and sex hormone receptors. Cancer 1986;58(7):1518—25.

70. Martin J.D., Hahnel R., McCartney A.J. The effect of estrogen receptor status on survival in patients with endometrial cancer. Am J Obstet Gynecol 1993;147(3):322—4.

71. Nyholm H., Christensen I.J., Nielsen A.L. Den prognostics betydning of progesteron receptoring hold ved endometrial cancer. Ugeskr Laeger 1997;159(5):601—4.

72. Palmer D.C., Muir I.M., Alexander A.I. The prognostic impor- tance of steroid receptors in endometrial carcinoma. Obstet Gynecol 1998;72(3):388—93.

73. Васильева Е.В., Белианин В.Л. Серозная аденокарцинома: критерии морфологического диагноза

74. и иммуногистохимия. Арх пат 2005;67(2):25—7.

75. Пожарисский К.М., Самсонова Е.А., Тен В.П. и др. Иммуногистохимический профиль эндометриоидной аденокарциномы тела матки: ER, PR, Her-2, Ki-67 и их прогностическое значение. Арх пат 2005;(2):13—7.


Для цитирования:


Лактионов К.П., Абдуллаева Г.М., Анурова О.А. КЛИНИКО-МОРФОЛОГИЧЕСКИЕ И МОЛЕКУЛЯРНО-БИОЛОГИЧЕСКИЕ ФАКТОРЫ ПРОГНОЗА РЕДКИХ ФОРМ РАКА ТЕЛА МАТКИ. Опухоли женской репродуктивной системы. 2008;(2):60-69. https://doi.org/10.17650/1994-4098-2008-0-2-60-69

For citation:


Laktionov K.P., Abdullayeva G.M., Anurova O.A. CLINICAL-MORPHOLOGIC AND MOLECULAR-BIOLOGIC PROGNOSTIC FACTORS FOR RARE FORMS OF UTERINE CANCER. Tumors of female reproductive system. 2008;(2):60-69. (In Russ.) https://doi.org/10.17650/1994-4098-2008-0-2-60-69

Просмотров: 177


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1994-4098 (Print)
ISSN 1999-8627 (Online)